MedPath

A randomized controlled trial comparing Vonoprazan, Amoxicillin, Metronidazole triple therapy and Rabeprazole, Amoxicillin, Metronidazole triple therapy as a second-line eradication of Helicobacter pylori

Not Applicable
Recruiting
Conditions
Helicobacter pylori infection
Registration Number
JPRN-UMIN000025801
Lead Sponsor
Yokohama City University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

A patient who has eradication history except triple therapy with Vonoprazan, Amoxicillin and Clarithromycin. Pregnancy or lactation. Past history of allergy for the drugs used in this study. A patient with brain and spinal cord disease. A patient with infectious mononucleosis. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patient who is disqualified for the study by physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Eradication rate assessed by urea breath test more than 8 weeks after treatment
Secondary Outcome Measures
NameTimeMethod
Safety evaluated by side effect questionnaire filled by patients
© Copyright 2025. All Rights Reserved by MedPath